Rr Dtc News Today

Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.

Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.

Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.

Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.

A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.